Toleranzia to merge with Flerie in a SEK136m deal.

Toleranzia, a Swedish biotechnology company specializing in immune-tolerance therapies for autoimmune orphan diseases, is set to merge with Flerie, a publicly listed life-science investment firm, in a SEK136m deal. ”Flerie, in its role as an active majority owner, has already significantly contributed to Toleranzia's positive development. We are approaching our first clinical trial in patients, and with the right financial conditions, there is great potential to create substantial value in the coming years. Thanks to Flerie's extensive investor network, a merger could open up more opportunities for long-term financing of the company on attractive terms. The proposed merger would strengthen the prospects for Toleranzia's pharmaceutical projects while allowing our shareholders to benefit from the value growth in Flerie's diverse investment portfolio," Charlotte Fribert, Toleranzia CEO.